Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2024-11-22 Regulatory Filings
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Rozpoczęcie współpracy w celu uruchomienia linii produkcyjnej umożliwiającej komercyjną produkcję paneli systemu BACTEROMIC - Content (PL)
Regulatory Filings Classification · 99% confidence The document is a 'raport bieżący' (current report) from a Polish entity (Scope Fluidics S.A.) detailing a significant operational agreement with TE Connectivity plc regarding the design and construction of a production line for their BACTEROMIC system. This agreement involves strategic collaboration, capital expenditure estimates (approx. 1 million EUR), and future commercial production plans. This type of announcement, which details a major business development, partnership, or strategic operational update that is not a standard financial report (like 10-K or IR) or a specific transaction (like DIRS or DIV), typically falls under general regulatory announcements or significant business updates. Since it is not a standard financial report, an earnings release, or a specific corporate action like a merger or share issue, it best fits the general regulatory announcement category, which is RNS in this classification scheme, as it is a material event disclosure.
2024-11-22 Polish
Rozpoczęcie procesu badań klinicznych panelu UNI systemu BACTEROMIC - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text is very short (883 characters) and appears to be a formal announcement in Polish regarding the commencement of clinical trials ('badania kliniczne') for the BACTEROMIC system, referencing previous current reports ('raport bieżący'). It discusses progress towards IVDR certification and timelines. This type of specific operational update, which is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), fits best under the general category for regulatory announcements that don't have a more specific code. Since it is a formal, non-standard update, the most appropriate fallback is Regulatory Filings (RNS).
2024-11-21 Polish
Otrzymanie 30 mln USD od Bio-Rad Laboratories, Inc. w związku z ostatecznym rozliczeniem Płatności Warunkowych - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document is very short (658 characters) and appears to be a formal announcement regarding a specific financial transaction or milestone related to a previous agreement (referencing report numbers 18/2024 and 13/2022). It details receiving a payment of 30 million USD and the final settlement of a transaction. This content relates to a significant corporate event, likely a financing outcome or a major contractual milestone payment. Since it is a brief, specific announcement that doesn't fit the detailed definitions of 10-K, ER, or IR, and it is not explicitly announcing the publication of a larger report (ruling out RPA), it best fits the general category for significant corporate announcements that don't have a more specific code. Given the context of a payment related to a transaction, it could potentially be CAP (Capital/Financing Update) or LTR (Legal Proceedings Report, if the payment was a settlement), but the language suggests a contractual milestone payment rather than a general financing round or lawsuit resolution. As a specific, non-standard announcement, the most appropriate fallback category is Regulatory Filings (RNS).
2024-11-06 Polish
Aktualizacja informacji nt. Płatności Warunkowych od Bio-Rad Laboratories, Inc. - Content (PL)
M&A Activity Classification · 99% confidence The document is a 'raport bieżący' (current report) from a Polish company (Scope Fluidics S.A.) detailing an agreement reached with Bio-Rad Laboratories Inc. regarding contingent payments related to a previous divestiture. It discusses the modification of payment terms, negotiation outcomes, and the impact on the company's financial outlook. This type of announcement, which reports on a significant corporate event, negotiation conclusion, or material change in financial expectations outside of standard periodic reports (like 10-K or IR), typically falls under general regulatory announcements or material event disclosures. Since it is not a specific announcement like a dividend (DIV), management change (MANG), or earnings release (ER), and it is a formal disclosure referencing MAR (Market Abuse Regulation), it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for material, non-standard disclosures, or potentially a Capital/Financing Update (CAP) due to the settlement involving a large cash payment, but RNS is safer for general material event reporting in this context. Given the nature of reporting on a settlement of contingent consideration from a prior transaction, RNS is the most appropriate general regulatory disclosure code.
2024-11-05 Polish
Informacja o przyznaniu patentu spółce Bacteromic przez Państwowy Urząd Własności Intelektualnej Ludowej Republiki Chin - Content (PL)
Regulatory Filings Classification · 100% confidence The document text describes the granting of a patent by the State Intellectual Property Office of the People's Republic of China to a subsidiary (Bacteromic) for a method and system for rapidly testing the sensitivity of microorganisms to antimicrobial agents. This relates to intellectual property rights and technological protection. Among the provided categories, 'IP' (Intellectual Property) is the most fitting classification for a patent announcement, as it directly concerns the company's proprietary technology rights.
2024-10-23 Polish
Raport biegłego rewidenta z przeglądu skróconego półrocznego sprawozdania finansowego Scope Fluidics S.A. obejmującego okres od 1 stycznia do 30 czerwca 2024 roku
Audit Report / Information Classification · 99% confidence The document is titled "RAPORT NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z PRZEGLĄDU ŚRÓDROCZNEGO SKRÓCONEGO JEDNOSTKOWEGO SPRAWOZDANIA FINANSOWEGO" (Report of the Independent Auditor on the Interim Condensed Individual Financial Statements) for the period ending June 30, 2024. It explicitly details the scope of a review conducted according to auditing standards (Krajowy Standard Przeglądu 2410 / ISRE 2410) and concludes with a finding regarding the interim financial statements. This content directly corresponds to the definition of an Audit Report / Information (AR), which covers standalone audit reports and results of internal/regulatory stress tests, distinct from a full Annual Report (10-K) or a simple Earnings Release (ER). The document is the audit/review report itself, not an announcement of its publication. H1 2024
2024-09-30 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.